Tenax Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Tenax Therapeutics generated cash of -$5,903,532, which is more than the previous year. Cash used in financing activities reached the amount of $13,569,137 last year. Net change in cash is therefore $7,668,448.
Cash Flow
| 2014 | -9.26M | -147.03K | 66.94M |
|---|---|---|---|
| 2015 | -9.74M | -40.92M | 280.59K |
| 2016 | -15.87M | 22.20M | 280.59K |
| 2017 | -12.14M | 3.74M | 498.49K |
| 2018 | -5.49M | 7.35M | 8.90M |
| 2019 | -7.55M | -1.65K | 96.5K |
| 2020 | -9.27M | 20.10K | 10.59M |
| 2021 | -10.85M | 452.60K | 9.73K |
| 2022 | -12.01M | -2.32K | 8.55M |
| 2023 | -5.90M | 2.84K | 13.56M |
TENX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.12M | 5.58M | 6.25M | 4.90M | 12.36M | 1.60M | 9.99M | 3.66M | 58.32M | 783.52K |
Operating activities | ||||||||||
Net income | -7.71M | -11.04M | -32.47M | -9.85M | -8.39M | -14.14M | -8.83M | -43.92M | -14.08M | -19.54M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 7.57K | 113.33K | 108.98K | 114.74K | 107.27K | 9.01K | 13.62K | 18.95K | 148.14K | 150.48K |
Stock-based compensation expense | 0 | 365 | 773 | 352 | 271 | 0 | 79.58K | 1.06K | 975 | 0 |
| Deferred income tax benefit | 0 | 365 | 773 | 352 | 271 | 0 | 79.58K | 1.06K | 975 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -305.69K | -980.82K | -22.5K | 698.37K | -322.66K | -122.60K | 1.11M | 23.80K | -793.14K | 519.25K |
Inventories | 305.69K | 0 | 544.58K | 535.55K | -883.04K | -729.35K | 4.99M | -2.72M | -2.72M | 99.20K |
Accounts payable | 1.88M | -344.95K | -544.58K | -535.55K | 883.04K | 729.35K | -4.99M | 2.72M | 2.72M | -2.08M |
Cash generated by operating activities | -5.90M | -12.01M | -10.85M | -9.27M | -7.55M | -5.49M | -12.14M | -15.87M | -9.74M | -9.26M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -345.54K | -596.52K | -618.1K | -493.82K | -299.17K | -7.25M | -55.14M | -55.14M |
Investments In Property Plant And Equipment | 2.84K | -2.32K | -5.25K | -3.49K | -3.57K | -7.59K | -4.53K | -2.88K | -109.65K | -147.03K |
Acquisitions Net | 0 | 0 | -457 | -23 | -1 | 0 | 0 | 75K | 105.42K | 6.5K |
Cash generated by investing activities | 2.84K | -2.32K | 452.60K | 20.10K | -1.65K | 7.35M | 3.74M | 22.20M | -40.92M | -147.03K |
Financing activities | ||||||||||
Common Stock Issued | 14.19M | 365.31K | 9.73M | 8.65M | 171.21K | 316.26K | 498.49K | 769.90K | 543.99K | 62.04M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -624.30K | 624.30K | 0 | -244.65K | 0 | 0 | 0 | 0 | 0 | -135.29K |
Cash used in financing activities | 13.56M | 8.55M | 9.73K | 10.59M | 96.5K | 8.90M | 498.49K | 280.59K | 280.59K | 66.94M |
Net Change In Cash | 7.66M | -3.46M | -666.31K | 1.34M | -7.46M | 10.76M | -8.39M | 6.33M | -50.39M | 57.53M |
Cash at end of period | 9.79M | 2.12M | 5.58M | 6.25M | 4.90M | 12.36M | 1.60M | 9.99M | 7.92M | 58.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |